Condition deep-dive · 6 min read

Cold sores / recurrent HSV-1 — what L-lysine, lemon balm, and zinc actually do

Updated 2026-05-16 · Reviewed by SupplementScore editors · No sponsorships

Recurrent herpes labialis affects 20–40% of adults at some point. The most effective interventions are prescription antivirals — episodic acyclovir, valacyclovir, or famciclovir taken at first prodrome reduces severity and duration meaningfully; daily suppressive valacyclovir cuts recurrence rates in frequent flares. The supplement layer has a small but defensible evidence base: L-lysine for recurrence reduction (Griffith and follow-on trials, modest effect), topical lemon balm (Melissa officinalis) extract for episode duration, and zinc oxide or zinc sulfate topicals for acute lesion management. Useful adjuncts, not substitutes for antivirals in frequent or severe cases.

Read this first. Genital herpes, ocular herpes (herpes keratitis), eczema herpeticum, neonatal HSV, and HSV in immunocompromised patients are different clinical situations that require specific medical management — not a cold-sore protocol. Cold sores in or near the eye, in someone with eczema, or with frequent flares (≥6/year) warrant clinical evaluation for prescription antivirals. Cold sores can be transmitted by contact with active lesions; avoid kissing infants, sharing utensils/lip products, and oral contact during active outbreaks.

What has trial evidence

Tier 2 evidence · Recurrence reduction (preventive)

L-Lysine (daily preventive)

1–3 g/day in divided doses for recurrence prevention; 3 g/day for 6 months in the most-cited Griffith protocol

The mechanism is competition with arginine for cellular uptake — HSV replication is arginine-dependent. Trial evidence is mixed but the Griffith 1987 trial and subsequent small RCTs show modest reductions in recurrence frequency and severity at 1–3 g/day. The effect size is smaller than prescription suppressive antivirals. Higher daily doses (above 3 g) do not appear to improve efficacy and may cause GI upset. Safe long-term; avoid in patients with arginine-deficiency conditions or on calcium-channel blockers (lysine-calcium interaction modest).

Tier 2 evidence · Acute episode duration

Lemon balm (Melissa officinalis) topical

1% Melissa cream applied to lesion 2–4× daily, starting at first prodrome

Koytchev 1999 and Wölbling 1994 RCTs of standardised lemon balm cream (1% LO-701 extract) showed reduced lesion healing time and severity when applied at first prodrome. Mechanism: tannins and rosmarinic acid with direct antiviral activity in vitro. Lower-evidence than docosanol or acyclovir cream but cheaper and well-tolerated. Best used as soon as tingling/prodrome is felt.

Tier 2 evidence · Acute lesion management

Zinc topical (zinc oxide or zinc sulfate)

Topical zinc oxide ointment or zinc sulfate solution applied to lesions 4× daily

Small trials (e.g., Brody 1981, Eby 1985) show topical zinc reduces episode duration and severity when applied promptly. Available OTC in formulations like Herpecin-L (with sunscreen and lysine) and generic zinc oxide products. The acute-lesion benefit is more solid than the systemic-zinc preventive claim — chronic systemic zinc supplementation in zinc-replete adults does not reduce cold sore recurrence.

Tier 1 evidence (OTC) · Acute episode

Docosanol 10% cream (Abreva)

5× daily at first prodrome until healed (typically 4–10 days)

Sacks 2001 (n=737) showed docosanol reduces healing time by approximately 0.5–1 day vs placebo when applied at first prodrome. The only FDA-approved OTC antiviral for cold sores. Modest effect size but consistent. Not a supplement but worth listing — OTC and often cheaper than the supplement alternatives.

The prescription-antiviral layer (where supplements are inadequate)

For frequent or severe recurrences, prescription antivirals dominate the supplement layer:

Episodic valacyclovir 2 g b.i.d. × 1 day (one-day course at first prodrome) — Spruance 2003 showed meaningful reduction in episode duration and lesion progression to ulcer.
Episodic famciclovir 1500 mg × 1 dose — comparable efficacy to short-course valacyclovir.
Daily suppressive valacyclovir 500 mg/day — for users with ≥6 flares/year; reduces recurrence frequency by 50–70%.
Topical acyclovir 5% cream or penciclovir 1% cream — modest acute benefit; less effective than oral therapy.

The behavioural / trigger-management foundation

Reducing reactivation triggers matters more than acute supplement timing in many users:

Sun exposure (UV) — well-documented HSV-1 reactivation trigger; use lip sunscreen with SPF 30+ daily on lips for users with frequent flares; reapply on outdoor days.
Sleep deprivation — protect sleep; recurrence often clusters with sleep loss.
Stress — physical or psychological stress is a common trigger; stress-management is part of long-term recurrence reduction.
Illness and fever — common reactivation context; supportive care during illness.
Menstrual cycle — many women note premenstrual flares; track to anticipate.
Dental procedures and lip trauma — common acute triggers; consider prophylactic antiviral around scheduled procedures.
Avoid sharing utensils/lip products and kissing during active lesions — minimises transmission.

What to skip

High-dose arginine supplements during active lesions — theoretical worsening; avoid arginine-rich pre-workout supplements during flares.
"Immune boost" megadose vitamin C, echinacea, etc. — no HSV-specific evidence; addresses different problem.
Colloidal silver topicals — argyria risk with chronic use; no evidence of benefit.
"Herpes cure" products marketed online — predatory and frequently the target of FTC/FDA enforcement; HSV is not curable, and infection is lifelong.
Topical hydrogen peroxide repeated applications — local tissue damage; may slow healing.
Hydrocortisone alone on active lesion — local immunosuppression may worsen; should be paired with antiviral if used.

What to track

Flare diary: date, duration (prodrome to healed), severity (0–10), suspected trigger, treatments used. Counting flares per year is the simplest functional metric. Reassess at 6 months of preventive lysine. If flares haven't reduced by 30% at 6 months of 2 g/day lysine, escalate to prescription suppressive antivirals (the supplement layer isn't adequate for frequent flares).

Practical quick-start. For an infrequent user (1–2 flares/year): topical Melissa cream or zinc oxide at first prodrome, plus daily SPF lip balm for UV trigger control. For a moderate user (3–5 flares/year): add L-lysine 1–2 g/day preventive; episodic prescription valacyclovir 2 g b.i.d. × 1 day at first prodrome is more effective than any topical. For a frequent user (≥6 flares/year): daily suppressive valacyclovir 500 mg/day; supplements become secondary.

Educational reference, not medical advice. Discuss any supplement change with a qualified clinician. Frequent or severe cold sores often warrant prescription antiviral therapy that supplements cannot replace.